AAM Strengthens Calls For Reforms To Stop Anticompetitive Tactics
Six Areas Listed Including Skinny Label Carve Outs
The US Association for Accessible Medicines discussed six areas for reform during a recent US Senate Judiciary Committee hearing “shining a spotlight on the anti-competitive tactics used by some brand name pharmaceutical companies to delay patient access” to generics and biosimilars.
